Skip to main content
SpringerLink
Log in

Duloxetine: a guide to its use in major depressive disorder

  • Drug and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Frampton JE, Plosker GL. Duloxetine: a review of its use in the treatment of major depressive disorder. CNS Drugs 2007; 21(7): 581–609

    Article  PubMed  CAS  Google Scholar 

  2. Cymbalta: summary of product characteristics. Basingstoke: Eli Lilly and Company Limited, 2006 Dec 17

  3. Cymbalta® (duloxetine hydrochloride) delayed-release capsules prescribing information. Indianapolis (IN): Eli Lilly and Company, 2007 Nov

  4. Eli Lilly and Company. FDA approves Cymbalta® for maintenance treatment of major depressive disorder [media release]. Available from: URL: http://www.lilly.com [Accessed 2007 Dec 7]

  5. Khan A, Schwartz K. Study designs and outcomes in antidepressant clinical trials. Essent Psychopharmacol 2005; 6(4): 221–6

    PubMed  Google Scholar 

  6. Brannan SK, Mallinckrodt CH, Brown EB, et al. Duloxetine 60mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005 Jan; 39(1): 43–53

    Article  PubMed  Google Scholar 

  7. Brecht S, Courtecuisse C, Debieuvre C, et al. Efficacy of duloxetine in the treatment of unspecified pain associated with depression. 15th European Congress of Psychiatry; 2007 Mar 17–21; Madrid

  8. Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder. Am J Psychiatry 2007; 164: 900–9

    Article  PubMed  Google Scholar 

  9. Mallinckrodt CH, Prakash A, Andorn AC, et al. Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range. J Psychiatr Res 2006; 40: 337–48

    Article  PubMed  Google Scholar 

  10. Brannan SK, Mallinckrodt CH, Detke MJ, et al. Onset of action for duloxetine 60mg once daily: double-blind, placebo-controlled studies. J Psychiatr Res 2005 Mar; 39(2): 161–72

    Article  PubMed  Google Scholar 

  11. Perahia DG, Gilaberte I, Wang F, et al. Duloxetine in the prevention of relapse of major depressive disorder. Br J Psychiatry 2006 Apr; 188: 346–53

    Article  PubMed  Google Scholar 

  12. Perahia DG, Wang F, Mallinckrodt CH, et al. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Psychiatry 2006 May 10; 21(6): 367–78

    Article  PubMed  CAS  Google Scholar 

  13. Eli Lilly and Company. Clinical study summary: Study F1J-MC-HMAT Study Group A [online]. Available from URL: http://www.lillytrials.com [Accessed 2007 Jan 9]

  14. Nierenberg AA, Greist JH, Mallinckrodt CH, et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin 2007 Feb; 23(2): 401–16

    Article  PubMed  CAS  Google Scholar 

  15. Khan A, Bose A, Alexopoulos GS, et al. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin Drug Invest 2007; 27(7): 481–192

    Article  CAS  Google Scholar 

  16. Perahia DG, Pritchett YL, Kajdasz DK, et al. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J Psychiatr Res 2008 Jan; 42(1): 22–34

    Article  PubMed  Google Scholar 

  17. Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004 Dec; 14(6): 457–70

    Article  PubMed  CAS  Google Scholar 

  18. Pigott TA, Arnold LM, Aaronson ST, et al. Duloxetine versus escitalopram and placebo in the long-term treatment of patients with MDD [abstract no. 13]. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20–25; Toronto (ON), 73

  19. Wade A, Gembert K, Florea I, et al. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin 2007; 23(7): 1605–14

    Article  PubMed  CAS  Google Scholar 

  20. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002 Apr; 63(4): 308–15

    Article  PubMed  CAS  Google Scholar 

  21. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002; 36(6): 383–90

    Article  PubMed  Google Scholar 

  22. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004 Aug; 24(4): 389–99

    Article  PubMed  CAS  Google Scholar 

  23. Hudson JI, Wohlreich MM, Kajdasz DK, et al. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol 2005 Jul; 20(5): 327–41

    Article  PubMed  CAS  Google Scholar 

  24. Nelson JC, Lu Pritchett Y, Martynov O, et al. The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials. Prim Care Companion J Clin Psychiatry 2006; 8(4): 212–9

    Article  PubMed  Google Scholar 

  25. Delgado PL, Brannan SK, Mallinckrodt CH, et al. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry 2005 Jun; 66(6): 686–92

    Article  PubMed  Google Scholar 

  26. Clayton A, Mallinckrodt CH, Wohlreich MM, et al. Sexual functioning in long-term treatment of MDD: duloxetine, escitalopram, and placebo [abstract no. NR199 plus poster]. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20–25; Toronto (ON), 83

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Duloxetine: a guide to its use in major depressive disorder. Drugs Ther. Perspect 24, 5–8 (2008). https://doi.org/10.2165/00042310-200824030-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200824030-00002

Keywords

Search

Navigation